Biologics/Biosimilars

(030) Utilization and patient characteristics for the originator and biosimilar trastuzumab products in the United States

(031) Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

(032) Exploitation of data available in open access on the consumption of medication in France: use case on anti-TNF biosimilars market penetration

(034) The Prescription Pattern of Biologics for Crohn’s Disease Patients in Taiwan

(037) Purchases of Biological Medicines by the Ministry of Health During the Approval of Biosimilars in Brazil

(038) Real-world evaluation of the persistence of the most used drug groups in Rheumatoid Arthritis from 2017 to 2021 in the Public Health System, Brazil

(039) Dispensation of Biologic and Non-Biologic Medication in the Brazilian Public Health System

(040) Persistence Associated With The Use Of Biologicals For The Treatment Of Ankylosing Spondylitis In The Brazilian Public Health System

(041) Predictors of effectiveness of biologic Disease-Modifying Antirheumatic Drugs (bDMARD) in the treatment of psoriatic arthritis

(042) Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: systematic review and meta-analysis

(043) Renal Adverse Events in Patients with Diabetic Macular Edema Receiving Intravitreal Vascular Endothelial Growth Factors Inhibitors